The lede: Every spring, Corteva gets covered like a weather derivative — drought in Iowa, planting delays, corn futures. That's the wrong chart. CTVA's margin structure is actually gated by a regulator most investors have never heard of: USDA's Animal and Plant Health Inspection Service (APHIS), which decides whether gene-edited seeds get treated as "regulated articles" requiring years of review or waved through as equivalent to conventional breeding. That gate — not rainfall — determines how fast Corteva can refresh its trait portfolio before older patents (Enlist, and the broader herbicide-tolerance stack) roll off and margin compresses toward generic-seed economics. APHIS's SECURE Rule, the Biden-era framework meant to fast-track low-risk gene-edited crops, was vacated by a federal court in December 2024. APHIS now has a rule ("Regaining Lost Efficiencies for Products of Biotechnology") queued for 2026 that would restore and potentially widen fast-track exemptions. Whichever administration's version lands, the timing of that rule is the real earnings catalyst — it dictates how many new proprietary traits Corteva can commercialize before the patent cliff bites.